With the erythrocyte assay, multiple examples of decreased uroporphyrinogen decarboxylase activity were detected in members of three families of patients with porphyria cutanea tarda. In two of these families subclinical porphyria was also recognized. The inheritance pattern was consistant with an autosomal dominant trait.
INTRODUCTION
Specific enzymatic defects in the porphyrin biosynthetic pathway have been defined in several types of inherited porphyria (acute intermittent porphyria, congenital erythropoietic porphyria, and protoporphyria) (1) (2) (3) (4) (5) . Assays for these enzymes have made family studies possible and the genetic characteristics of the diseases have been documented (6, 7) .
In contrast, a specific enzymatic defect has not been defined in porphyria cutanea tarda (PCT) .' This disease is usually considered to be an acquired disorder of porphyrin metabolism because of its onset late in life and common association with alcoholic liver disease (8, 9) .
Biochemically PCT is characterized by hepatic synthesis and urinary excretion of excessive amounts of porphyrins, particularly uroporphyrin I and smaller amounts of 7-carboxyl porphyrin (10) (11) (12) . The preponderance of uroporphyrin I and 7-carboxyl porphyrin in both the liver and urine suggests that the enzymatic decarboxylation of the reduced forms of these compounds (porphyrinogens) to coproporphyrinogen I is impaired. This decarboxylation is catalyzed by the enzyme tiroporphyrinogen decarboxylase (URODECARB) (13) (Fig. 1) .
The finding of hepatic siderosis in virtually all patients with PCT and the clinical benefits of phlebotomy therapy (14) (15) (16) have raised the possibility that iron might play an important part in the etiology of the disease. In support of this hypothesis it has been shown, in an in vitro model system, that iron 'Abbreviations used in this paper: ALA, 8 1 The enzymatic pathway for the biosynthesis of heme.
(1) = ALA synthetase, (2) = ALA dehydratase, (3) = uroporphyrinogen I synthetase, (4) = uroporphyrinogen III cosynthetase, (5) = uroporphyrinogen decarboxylase, (6) = coproporphyrinogen oxidase, (7) = heme synthetase, ALA = 8-aminolevulinic acid, PBG = porphobilinogen; URO'GEN = uroporphyrinogen, COPRO'GEN = coproporphvrinogen, PROTO = protoporphyrin.
alters hepatic porphyrin metabolism in a way that parallels the abnormalities observed in PCT (17) . However, the vast majority of patients with alcoholic liver disease and hepatic siderosis do not develop PCT. This clinical observation has led to speculation that patients with PCT have an occult genetic abnormality expressed only when the liver cell is injured in a specific way (18) . The concept that there may be a genetically determined contribution to the pathogenesis of PCT has been strengthened by occasional reports describing a familial occurrence of the disease (19, 20) . In addition, several reports have described abnormalities of porphyrin metabolism in apparently unaffected relatives of patients with PCT (21, 22 URODECARB was assayed by a previously published method by utilizing enzymatically generated, tritiated uroporphyrinogen as the substrate and thin layer chromatographic identification and liquid scintillation quantitation of the reaction products (25) .
Hepatic porphyrin content was quantitated by analysis of the pellet and the remaining supemate from the centrifuged homogenates. These were both extracted with 2.0-ml aliquots of 3.0 N HC1 until no fluorescence was observed in the eluates. The HC1 concentration was then adjusted to 1.5 N, and the porphyrin content was measured spectrophotometrically by scanning the spectrum from 370 to 440 nm with a Cary spectrophotometer (Cary Instruments, Fairfield, N. J.) and applying the correction factors of With (26) . The porphyrins were then adsorbed on talc and esterified in H,SO4-methanol (27) . Porphyrins were then identified chromatographically by the method of Doss (28) .
Urine porphyrin concentrations were determined by a previously published method (29) . Chromatographic identification of the urinary porphyrins was done as described above for hepatic porphyrins. Isomers of uroporphyrin were identified by decarboxylation to coproporphyrin (30) and lutidine x H,O chromatography (31 Erythrocyte URODECARB activity was measured in 56 normal subjects, 29 males and 27 females. In all the subjects, the hemoglobin concentration was normal, as was the volume of packed erythrocytes, and the reticulocyte count. The enzymatic activity in erythrocytes appeared to differ according to sex. The mean enzymatic activity in male subjects was 0.38 U/mg Hb (range 0.33-0.45) and in the female subjects was 0.26 U/mg Hb (range 0.18-0.36) ( Table  I ). Enzymatic activity did not increase by freeze thawving the ervytrocytes more thani twice after soniicationi.
In 12 normal subjects, erythrocyte URODECARB activity was determined with uroporphyrinogen III as the substrate in the assay system. Results did not differ appreciably from those obtained from simultaneously performed assays with uroporphyrinogen I as the substrate (Table II) . The patient was instruicted to abstain from alcohol and was treated with six phlebotomies of 500 ml each. The urinary excretion of uroporphyrin decreased towards normal and the skin lesionis cleared entirely (Fig. 2) . Some 30 wk after the initial studies were done, a liver biopsy was repeated. T. E.'s parents were deceased but he had two living siblings, a sister, M. C., and a brother, E. E. M. C., a 64-yr-old woman, was in good health but had noticed increasing amounts of facial hair in recent years. She consumed two martinis daily. Urinary excretion of uroporphyrin ranged from 950 to 1, 410 ,ug/day, which was predominantly uroporphyrin I. (Table III) . Thus in this family, of the three siblings studied, two had clinically detectable PCT with decreased hepatic and erythrocyte URODECARB activity (Table III) . The third sibling, a regular blood donor, did not have clinical symptoms of PCT but erythrocyte URODECARB activity was reduced (Table III) (Table III) . With uroporphyrinogen III as the substrate the erythrocyte URODECARB activity was 0.14 U/mg Hb. A remission was obtained after phlebotomy therapy with clearing of the skin lesions and return of the urinary porphyrin excretion towards normal. A followup liver biopsy was not carried out but subsequent determinations of erythrocyte URODECARB activity showed no change in the enzymatic activity.
The patient's parents were deceased but a paternal uncle (Ia, Fig. 3 and Table III), a maternal aunt (Id), two of her four siblings (IIb and lIc), her only child, a son (IIIa), and three grandchildren (IVa, IVb and IVc) were studied. None had clinical manifestations of porphyria, and only the son, a heavy drinker, had an increased urine uroporphyrin level. Values for erythrocyte URODECARB were decreased in six of the nine family members, including representatives in each of four generations.
Studies in family 3. The index patient, G. H., a 25-yr-old white man, was a heavy drinker. He was initially evaluated in November, 1974, at the Salt Lake V. A. Hospital because of a bullous, photosensitive dermatitis. The clinical diagnosis of PCT was confirmed by finding an increased value for 24 h urinary uroporphyrin excretion (Table III) The predominant hepatic porphyrin was found to be uroporphyrin; a small amount of 7-carboxyl porphyrin was also noted. Hepatic and erythrocyte URODE-CARB activities were distinctly subnormal (Table  III) . With uroporphyrinogen III as the substrate the erythrocyte URODECARB activity was also subnormal, 0.18 U/mg Hb.
The patient's parents were both decreased but three siblings, all females (ages 25-32 yr) were studied. All admitted to occasional social use of alcohol. None used oral contraceptives. None had skin disease, and all had normal urinary porphyrin determinations. Two of the sisters had normal erythrocyte uroporphyrinogen decarboxylase activity but the third had a subnormal value. The findings in this family are summarized in Table III. Additional studies. In addition to the four porphyric livers studied above, hepatic URODECARB activity was determined on needle biopsy specimens from two other unrelated patients with porphyria cutanea tarda. Grade I parenchymal siderosis was present in one specimen and grade 2 in the other. Subnormal URODECARB activity was found in both. The results of the six porphyric hepatic URODE-CARB assays are compared with the results in seven normal individuals in Fig. 4 (12) . URODECARB activity was decreased not only in hepatic tissue but also in the erythrocytes of patients with PCT. Decreased URODECARB activity in two heme-forming tissues suggests that an inherited, generalized metabolic defect is present. The erythrocyte assay provided a convenient tool for studying URODECARB activity in family members of patients with PCT. By means of this assay, in the first family studied (family 1), a clinically apparent but unrecognized case of PCT was discovered in the sister of the propositus. Similarly in family 2, the son of the propositus was found to have subclinical PCT as manifested by increased urinary excretion of uroporphyrin. Thus, this finding may serve to alert carriers to their increased risk of acquiring porphyria on exposure to alcohol and other hepatic toxins.
The deficiency in erythrocyte URODECARB appeared to be inherited as an autosomal dominant trait. In family 2, decreased erythrocyte URODE-CARB activity was discovered in four generations (Fig. 3 , Table III ). Clinically apparent PCT, or a detectable increase in the urinary excretion of uroporphyrin, was found only in individuals who consumed alcoholic beverages in large amounts.
The reduction of URODECARB activity to about 60% of normal in erythrocytes (Fig. 5) is not inconsistant with a heterozygous state. However, the reason for the apparently greater reduction in hepatic URODECARB activity is not clear from these studies. Perhaps acquired or environmental factors affecting only the liver are additive to the genetic defect. Iron overload alone probably does not account for this finding, since removal of iron by phlebotomy did not change hepatic URODECARB activity in the propositus in family 1. The assay, however, is performed with highly diluted homogenates, a procedure which may eliminate the iron effect.
A single enzyme is probably responsible for the decarboxylation of the four acetic acid side chains of uroporphyrinogen, but the first decarboxylation proceeds more readily then the next three (13) . We have reported that iron, an inhibitor of URODECARB, exerts its major inhibitory effect upon the removal of the second carboxyl group, leading to the accumulation of uroporphyrin and 7-carboxyl porphyrin in an in vitro hepatic model of PCT (25) . Histologic evidence of excessive hepatocellular iron was found in specimens from all of the patients studied here, a finding that is virtually uniform in PCT (16) . However, the absence of PCT in most patients with either primary or secondary hemochromatosis makes it unlikely that iron is the sole etiologic factor in the pathogenesis of PCT. The finding of normal hepatic URODECARB activity in the single patient with hemochromatosis studied lends support to this hypothesis. An underlying biochemical defect in patients with PCT, that results in unusual sensitivity to the effects of iron (and perhaps other toxic agents), seems a more plausible possibility. Such a biochemical defect was found in the liver and erythrocytes of all PCT patients studied. Thus, the concordance of an inherited defect (decreased URODECARB activity) and an acquired factor (hepatic siderosis) seems to be required for the clinical expression of PCT. Of interest in this regard was the finding that in the brother of the propositus in family 1, a very minimal increase in urinary uroporphyrin excretion was detected, even though his alcohol consumption was large, and URODECARB activity was decreased in his erythrocytes. This individual was a regular blood donor and thus may have had "prophylactic" phlebotomy therapy.
In normal subjects the erythrocyte URODECARB activity differed according to sex, with females demonstrating lower activities than males. In addition, four males with prostatic cancer, who were ingesting estrogens were found to have erythrocyte URODE-CARB activities in the normal female range. Thus, estrogens appear to lower URODECARB activity. This finding is of interest as PCT has been reported in individuals receiving estrogen therapy (32) (33) (34) . Also relevant is the observation that chronic male alcoholics, who represent the largest group of patients with PCT, frequently have testicular atrophy (35) and increased estrogen levels. However the relatively rare occurrence of PCT in individuals receiving estrogens and in chronic alcoholics suggests that estrogens alone do not reduce URODECARB activity enough to cause a clinically recognizable alteration in porphyrin metabolism. As in the case with iron, it is likely that estrogen-induced PCT occurs only in individuals with an underlying biochemical defect.
The hepatic URODECARB assays reported herein were all performed by using uroporphyrinogen I as the substrate in the assay system. URODECARB in erythrocyte hemolysates from nonporphyric individuals was active in decarboxylating uroporphyrinogen I and III to an equivalent degree (Table II) . Hemolysates from the patients with PCT demonstrated decreased URODECARB activity with either substrate and, as with the controls, there was no difference in the activity of the erythrocyte enzyme in decarboxylating uroporphyrinogen I or III.-The equivalent decarboxylation of either substrate is in agreement with the findings of Romeo and Levin for mouse spleen URODECARB (36) and our own finding for porcine hepatic URODECARB (25) . Although older data suggest that the rate of decarboxylation is higher with the type III isomer (37) (38) (39) , Inherited Enzymatic Defect in Porphyria Cutanea Tarda 1095 the current studies support the validity of assaying human hepatic URODECARB with uroporphyrinogen I as the substrate. If URODECARB deficiency is the underlying defect in heme biosynthesis in PCT, then the question arises as to why no heme deficiency is observed. Ordinarily an enzymatic defect would be expected to result in a deficiency of the end product of the metabolic pathway involved. However, this generalization does not hold true for most porphyrias. Hepatic heme synthesis in PCT has not been extensively studied. However, the lack of anemia in most patients with PCT speaks against a decrease in the synthesis of heme by the erythrocyte.
Classically, the 8-aminolevulinic acid (ALA) synthetase reaction is considered to be the rate controlling step in the porphyrin biosynthetic pathway (13) . Increased ALA synthesis could compensate for a partial block later in the pathway, and such a compensation occurs in acute intermittent porphyria and certain other porphyrias (40) . However, the hepatic synthesis of ALA is probably not increased in PCT. Studies with techniques which discriminate ALA from other aminoketones have revealed normal ALA synthetase activity in liver biopsy specimens from patients with PCT (1, 40, 41 ). An increase in the synthesis of uroporphyrinogen despite normal ALA synthetase activity suggests a regulatory mechanism later in the heme biosynthetic pathway. We previously reported that, under conditions which inhibit both URODECARB and uroporphyrinogen III cosynthetase (heating or the addition of ferrous iron) uroporphyrin synthesis from porphobilinogen in crude liver extracts was greatly increased (17) . These studies suggest a regulatory effect on uroporphyrinogen I synthetase activity by URODECARB and(or) uroporphyrinogen III cosynthetase. Such a regulatory effect might explain the increased activity of hepatic uroporphyrinogen I synthetase that has been reported by others in a small number of patients with PCT (1, 2) . The mechanism of this regulatory effect is unknown at present.
The predominance of the I series isomer in the hepatic and urinary porphyrins in PCT suggests that uroporphyrinogen III cosynthetase might also be impaired. This enzyme, like URODECARB, is inhibited by ferrous iron (17) . Furthermore, uroporphyrin III and uroporphyrinogen III are potent inhibitors of the cosynthetase (42) and the accumulation of these compounds resulting from impaired activity of URODECARB could lead to the synthesis and accumulation of uroporphyrin I, by its secondary effects on cosynthetase. The detection of decreased cosynthetase activity may be difficult in vitro because of the dilution of the proposed inhibitors (uroporphyrin and iron) inherent in the assay system. De-1096 J. P. Kushner, A. J. Barbuto, and G. R. Lee creased activity of uroporphyrinogen III cosynthetase is not incompatible with an overall increase in heme synthesis as has been discussed by Levin (43) . The studies reported herein suggest that PCT occurs in patients with a genetically detennined abnormality leading to reduced URODECARB activity. The decreased enzymatic activity appears to be inherited as an autosomal dominant trait. Family studies suggest that the disease remains latent until excessive hepatic iron stores accumulate.
